Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A drug being developed by biopharmaceutical company CombinatoRx has failed to reach its primary endpoint of reducing inflammation in patients with a bacterial gum disease in a trial.
Subscribe to our email newsletter
This trial was designed to determine how CRx-150, an immuno-modulating agent, would affect various systemic inflammatory markers in individuals with periodontitis in both the acute and chronic phase of immuno-inflammation.
The drug, CRx-150, did not reduce C-reactive protein (CRP) in the chronic inflammatory phase, the primary endpoint of the trial, as measured after 42 days.
There were small or no differences between CRx-150 and placebo for the other inflammatory markers measured including IL-1, IL-8, IL-12 and IFN-gamma.
“Further study of CRx-150 will be required to understand the magnitude of its effects, given the activity in the acute phase of this model, and we look forward to results of the CRx-150 phase II trial in patients with rheumatoid arthritis expected in the first half of 2007,” commented Alexis Borisy, president and CEO of CombinatoRx.